Calluna Pharma Completes Enrollment in Phase II AURORA Study for Idiopathic Pulmonary Fibrosis

Calluna Pharma Completes Phase II Enrollment for IPF Drug

The idiopathic pulmonary fibrosis (IPF) market is gaining significant attention, projected to grow from nearly $3 billion in 2025 to $7 billion by 2035, driven by substantial unmet needs. Current approved therapies, such as Ofev and Esbriet, only slow disease progression by about 50% annually and often lead to discontinuation due to poor tolerability. Calluna Pharma is addressing this by developing CAL101, a novel therapy targeting the S100A4 protein to halt scar tissue formation. The company recently completed enrollment for its Phase II AURORA study, aiming to provide a more effective and tolerable treatment option for IPF patients.

• The global idiopathic pulmonary fibrosis (IPF) market is poised for significant growth, estimated to reach nearly $7 billion by 2035 from $3 billion in 2025. This expansion is fueled by the critical unmet need for therapies that can halt disease progression, as current approved treatments like nintedanib and pirfenidone only slow the disease by approximately 50% annually and do not address underlying drivers of fibrosis.
• Calluna Pharma is advancing CAL101, a novel investigational drug designed to target the S100A4 protein, which plays a key role in scar tissue formation characteristic of IPF. The company recently announced the successful completion of enrollment for its Phase II AURORA study, marking a significant step towards developing a therapy that could potentially arrest the disease rather than just slowing its progression.
• A major challenge with existing IPF treatments is poor tolerability, particularly gastrointestinal issues, leading to high discontinuation rates. CAL101 aims to offer an improved tolerability profile alongside enhanced efficacy. Furthermore, success in IPF could establish a proof of concept for CAL101's application in other fibrotic conditions, including end-stage kidney disease, fibrotic liver disease, and systemic sclerosis, highlighting its broad therapeutic potential.

Addressing the Unmet Needs in Idiopathic Pulmonary Fibrosis Treatment

Current IPF treatment faces significant challenges despite recent therapeutic advances. While two antifibrotic agents have been approved, substantial limitations persist across diagnostic, therapeutic, and patient care domains. These challenges underscore the continued unmet medical need in IPF management.

• Limited efficacy of approved therapies - Pirfenidone and nintedanib slow but do not reverse disease progression, with no curative treatment available other than lung transplantation, and no verified evidence that these agents significantly alleviate the main clinical manifestations of IPF

• Diagnostic uncertainty in clinical practice - The 2011 ATS/ERS guidelines focused primarily on 'definite' IPF cases, leaving a lack of management guidance for 'probable' and 'possible' IPF, which represent highly prevalent clinical scenarios

• Tolerability and safety concerns - Pirfenidone is associated with significantly higher incidence of gastrointestinal, skin, nervous system, and liver function-related adverse events compared to controls, while both approved agents have limitations in tolerability

• Unclear impact on patient-reported outcomes - No definite proof indicates that pirfenidone and nintedanib can significantly ameliorate symptoms and quality of life in IPF patients, with the effect on patient-reported outcomes not yet fully understood

• Treatment controversies and variability - The appropriate indications for initiating therapy, best candidates for treatment, and possible role for combination therapy remain controversial, with treatment response varying among patients

• Limited short-term hospital outcomes - Antifibrotics were not observed to affect utilization of mechanical ventilation, ICU treatment during index admission, or 30-day mortality during respiratory-related hospitalizations

• Geographic disparities in treatment access - Significant variation exists in antifibrotic drug initiation, with Swedish patients showing 69.4% treatment rates compared to 29.6% in Finnish patients during 2014-2016 registry follow-up

Exploring Novel Targets to Halt IPF Progression

Recent research has identified several promising therapeutic targets that represent significant advances beyond current IPF treatments. The WT1-MYCN-PLK1 axis has emerged as a novel pathway where proto-oncogene MYCN, upregulated in dysregulated IPF fibroblasts, is induced by TGFα via Wilms tumor 1 (WT1) transcription factor. Volasertib, a PLK1 inhibitor, demonstrated efficacy in attenuating fibroblast activation and collagen deposition in preclinical models. Similarly, phosphodiesterase 4B (PDE4B) inhibition with BI-1015550 has shown superior performance compared to nintedanib and pirfenidone by targeting eight key molecules including PTGS2, VCAM1, and MMP1 through NF-κB pathway suppression. The angiotensin type II receptor (ATR) agonist C21 (buloxibutid) represents the first-in-class oral therapy in this category, having rapidly advanced to clinical trials with established safety profiles.

Lipid metabolism pathways have gained attention through lysophosphatidic acid receptor 1 (LPAR1) antagonism using PIPE-791, which demonstrated potent anti-fibrotic effects (IC 1.1 nM) in human lung fibroblasts with unique pharmacokinetic properties showing 20-fold increased potency with extended dosing intervals. The pneumocyte-macrophage paracrine lipid axis has been elucidated through nintedanib transcriptomic analyses, revealing how oxidized lipids alter macrophage activities and lead to lipid-filled macrophage formation. Additionally, TAM receptors (Tyro3, Axl, and Mer) represent another emerging target, with R428 (Axl-specific inhibitor) significantly reducing pro-fibrotic markers ACTA2, COL1A1, and FN1 in both healthy and IPF fibroblasts.

Novel approaches targeting immune regulation and cellular mechanisms include MyD88 homodimerization inhibition using TJ-M2010-5, which improved survival rates from 40% to 80% in bleomycin models through autophagy pathway modulation. Fibroblast activation protein (FAP)-targeted CAR T cell therapy represents a groundbreaking immunotherapeutic approach using lipid nanoparticle-encapsulated mRNA to generate CAR T cells in vivo for selective fibroblast elimination. Traditional medicine-derived targets include the TGF-β1/Hedgehog and HIF-1 signaling pathways targeted by Dahuang Zhechong pill, and FSTL1/NF-κB axis modulation through compounds like quercetin, demonstrating the potential for repurposing established therapeutic frameworks for IPF treatment.

CAL101's Potential Beyond IPF: A Gateway to Fibrotic Diseases

CAL-101 (idelalisib) has demonstrated significant clinical activity across multiple hematologic malignancies, with its primary therapeutic focus being B-cell cancers rather than fibrotic diseases. The drug has received FDA approval for chronic lymphocytic leukemia (CLL) in combination with rituximab, specifically for relapsed disease where rituximab monotherapy would be appropriate due to patient comorbidities. In CLL trials, idelalisib showed an 81% overall response rate with 92% overall survival at 12 months, though first-line studies were discontinued due to unacceptable infection-related mortality. The agent is also approved for follicular lymphoma and small lymphocytic lymphoma, with approval based on phase II trials in indolent non-Hodgkin lymphoma that demonstrated a 47% overall response rate in heavily pretreated patients.

The intervention models employed in idelalisib trials have primarily utilized randomized controlled designs for pivotal studies. The FDA approval was supported by a phase III randomized trial comparing rituximab monotherapy versus idelalisib plus rituximab in 220 heavily pre-treated CLL patients, representing a parallel assignment design with idelalisib administered at 150 mg orally twice daily. Early phase studies included dose-escalation phase I trials evaluating eight different dosing regimens ranging from 50 to 350 mg taken once or twice daily, followed by phase II expansion cohorts in specific disease populations.

Given the scarcity of direct head-to-head comparative trials, researchers have employed indirect treatment comparison methodologies, including network meta-analyses using the Bucher method with common comparator arms such as ofatumumab. These comparative approaches have been necessary to establish relative treatment efficacy against other targeted therapies in the B-cell malignancy treatment landscape, where idelalisib's role as a PI3Kδ inhibitor targets hyperactivated B-cell receptor signaling pathways.

IPF's Next Chapter: Can CAL101 Halt the Fibrotic March?

Idiopathic pulmonary fibrosis (IPF) remains a devastating and progressive lung disease, with patients facing a median survival of just 2-3 years post-diagnosis. While the approvals of pirfenidone and nintedanib marked a significant shift, these therapies primarily slow the decline in lung function, and their tolerability profiles often lead to treatment discontinuation. This leaves a substantial unmet need for more effective and better-tolerated options, a gap that Calluna Pharma aims to fill with CAL101.

CAL101 represents a promising new frontier by targeting the S100A4 protein, a key mediator in the activation and proliferation of lung fibroblasts and the subsequent formation of scar tissue. Research indicates that S100A4 is secreted by M2 polarized alveolar macrophages and promotes fibrosis, making its inhibition a logical strategy to potentially halt the disease's relentless progression. This mechanism of action is distinct from current antifibrotics, offering the potential for a first-in-class therapy that could fundamentally change the treatment paradigm.

The successful completion of Phase II AURORA study enrollment is a critical step. If CAL101 can demonstrate superior efficacy, such as a more significant impact on halting fibrosis, alongside an improved tolerability profile, it could lead to better patient adherence and long-term outcomes. Furthermore, S100A4's role as a potential biomarker could facilitate earlier diagnosis and more targeted interventions. However, the path forward is not without challenges. CAL101 must clear a high bar, proving its clinical superiority over existing treatments that have established efficacy in slowing FVC decline. Its tolerability in a broader patient population must also be confirmed, as any new adverse events could limit its adoption. The competitive landscape for IPF is also evolving, with ongoing research into new therapies, meaning CAL101 will need to demonstrate clear advantages to secure its place in a market projected for significant growth.